Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025.

ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $29.06, along with a high estimate of $38.00 and a low estimate of $22.00. Observing a ...

Contemporary research has brought psychosis out of the dark, transforming our relationship to it from one of fear and rejection to one of hope and recovery.